Dansk | English
Sitemap
youtube_off.png
linkedin_off.png
Facebook
News

News

Dato
11.05.2016
SANIFIT EXPANDS BOARD WITH SENIOR HIRE
Palma de Mallorca, Spain, May 10, 2016 - Laboratoris Sanifit S.L., a clinical-stage biopharmaceutical company focused on treatments for calcification disorders, today announces the appointment of Keith R. Leonard to the Board of Directors. Mr Leonard brings over 20 years of industry experience to Sanifit
Dato
21.04.2016
Enterome raises €14.5 million in Series C financing round Nestlé Health Science invests alongside existing investors
Paris, France and Boston, MA – April 20, 2016. ENTEROME Bioscience SA, a pioneer in the development of pharmaceuticals and diagnostics
based on the gut microbiome, announces that it has raised €14.5 million in a Series C financing round. The round was led by existing investors, such as Seventure (including from its new Health for Life Capital fund) and Lundbeckfond Ventures, and included new investors. Nestlé Health Science
also participated in the round as a new strategic investor. Financial terms of the investment were not disclosed.


Dato
19.04.2016
Enterome in-licenses novel compounds from Vertex Pharmaceuticals to treat microbiome-related inflammatory bowel diseases
ENTEROME Bioscience SA, a pioneer in the development of pharmaceuticals and diagnostics based on the gut microbiome, has signed an exclusive worldwide license agreement with Vertex Pharmaceuticals Inc. (Nasdaq:VRTX) to research, develop and commercialize novel small molecule FimH antagonists for use in the treatment of inflammatory bowel diseases (IBD).
Dato
14.04.2016
Cydan Development Announces Formation of Imara Inc. with $31M Series A Funding to Develop Therapeutic for Sickle Cell Disease
Cambridge, Mass., April 14, 2016 – Cydan Development, Inc., an orphan drug accelerator dedicated to creating therapies that improves the lives of people living with rare genetic diseases, today announced the launch of Imara, Inc. This is the second orphan drug company launched by Cydan since 2015. Imara will develop IMR-687, a disease-modifying therapeutic selected specifically for the treatment of sickle cell disease and other hemoglobinopathies. IMR-687 was discovered by H. Lundbeck A/S.
Dato
30.03.2016
ACACIA PHARMA INITIATES SECOND PIVOTAL PHASE 3 TREATMENT STUDY WITH BAREMSIS™ (APD421) IN POST-OPERATIVE NAUSEA & VOMITING (PONV)

NDA filing expected in second half of 2016

Cambridge, UK – 21st March 2016: Acacia Pharma Group plc (“Acacia Pharma”), the supportive care company developing products for US and international markets, announces the initiation of its second pivotal Phase 3 treatment study, investigating BAREMSIS™ (amisulpride injection, formerly APD421) in surgical patients who develop post-operative nausea & vomiting (PONV), despite having received antiemetic prophylaxis before surgery.  

Dato
14.03.2016
PSIOXUS THERAPEUTICS INITIATES COMBINATION OF PACLITAXEL WITH ONCOLYTIC VIRUS ENADENOTUCIREV IN OVARIAN CANCER STUDY
OXFORD – 10 MARCH 2015 – PsiOxus Therapeutics Ltd. (PsiOxus), the immunooncology company, today announced the first treatment of a patient to combine paclitaxel with the oncolytic virotherapy enadenotucirev in the OCTAVE (Ovarian Cancer Treated with Adeno Vaccine Enadenotucirev) study. The OCTAVE study will assess the safety, tolerability and efficacy of intraperitoneal enadenotucirev when combined with intravenous paclitaxel. In earlier phase I clinical trials, enadenotucirev has been shown to reach and selectively infect cancer cells when administered by intravenous infusion.
Dato
09.03.2016
Veloxis Pharmaceuticals publishes Annual Report 2015
Veloxis Pharmaceuticals A/S (OMX: VELO) (‘Veloxis') today published the annual report of Veloxis Pharmaceuticals A/S for the financial year 2015, and has entered into a long-term loan and security agreement.
Dato
09.03.2016
Veloxis Pharmaceuticals A/S moves Danish activates to the U.S.
Veloxis Pharmaceuticals A/S ("Veloxis") has decided to close its office in Hørsholm, Denmark, and move all activities to the U.S. where most of the company's current activities is already located. The process is expected to be completed during the second half of 2016.
Dato
07.03.2016
Vtesse, Inc. Announces Phase 1/2 Clinical Data Showing Slowing of Disease Progression from VTS-270 Treatment for Niemann-Pick Type C1 Disease
GAITHERSBURG, Md., March 4, 2016 /PRNewswire/ -- Vtesse, Inc. announced today data from a Phase 1/2 clinical trial demonstrating a reduction in the rate of Niemann-Pick Type C1 (NPC1) Disease progression from Vtesse's lead drug candidate VTS-270. The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and the National Center for Advancing Translational Sciences, two components of the National Institutes of Health, collaborated closely with patients, patient advocacy groups and academia to initiate the drug development phase for VTS-270. Vtesse is leading the late-stage formal drug development process.
Dato
03.03.2016
scPharmaceuticals Announces Positive Results from Pivotal Trial of Second Program – Subcutaneous Ceftriaxone for Treatment of Bacterial Infections
Antibacterial coverage (time over MIC) equivalent to coverage following standard intravenous administration.
Novel route of administration is free from common and serious risks associated with intravenous infusion lines and deep intramuscular injections.


LEXINGTON, Mass., March 2, 2016 /PRNewswire/ -- scPharmaceuticals, Inc., announced today that the pivotal trial for its ceftriaxone program met the targeted end-points. The primary end-point for the study is non-inferior antimicrobial coverage when compared to the same dose given by intravenous infusion. Antimicrobial coverage refers to time over the Minimum Inhibitory Concentration (MIC), a generally accepted measure of the adequacy of plasma levels of an antibiotic for treatment of infections due to susceptible bacteria.

Forrige 1 2 3 4 5 6 7 8 9 10 Næste 10 Næste